Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
5-HT2A receptor(Serotonin 2a (5-HT2a) receptor) | 1 |
GPCR(G-protein coupled receptor) | 1 |
Target |
Mechanism EDG6 agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Oct 2023 |
Target |
Mechanism PGI2 receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism 5-HT2A receptor inverse agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date16 Dec 2022 |
Sponsor / Collaborator ![]() [+1] |
Start Date28 Dec 2021 |
Sponsor / Collaborator ![]() [+1] |
Start Date10 Sep 2021 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Temanogrel ( 5-HT2A receptor ) | Thrombosis More | Phase 1 |
AN-659 | Neuritis More | Preclinical |
Undisclosed Orphan CNS GPCR Modulator(Arena/ Boehringer) ( GPCR ) | Schizophrenia More | Discovery |
Lorcaserin Hydrochloride ( 5-HT2C receptor ) | Obesity More | Withdrawn |
Etrasimod Arginine ( S1PR1 x S1PR4 x S1PR5 ) | Skin Manifestations More | Discontinued |